Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Corrado Campochiaro und 17 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Inflammation, Fibrosis and Ageing Initiative, Scientific Institute for Research Hospital…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Immunosuppressive Agents, Scleroderma, Systemic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear. The objective of this study was to analyze treatment trends and the effect of IST and antifibrotic treatments on ILD progression using the European Scleroderma Trials and Research database.
Methods
We included patients with SSc‐ILD meeting the 2013 American College of Rheumatology/EULAR criteria with high‐resolution computed tomography–confirmed ILD, pulmonary function, and therapy data, grouped into four time periods (≤2006, 2007–2011, 2012–2016, and ≥2017). We analyzed IST initiation, switching, discontinuation, and combination therapy. ILD progression was defined as a decline in the percentage of predicted forced vital capacity of 5% or greater or the percentage of predicted diffusing capacity of the lungs for carbon monoxide of 10% or greater over 12 ± 3 months.
Results
Among 1,409 patients, IST use at first evaluation increased significantly from 13.6% (≤2006) to 57.4% (≥2017) ( P < 0.001). Mycophenolate mofetil emerged as the most prescribed IST (7% to 57%) ( P < 0.001). Combination therapy rose from 17.9% to 26.9% ( P < 0.001), whereas ILD progression rates declined from 21.3% (2007–2011) to 12.1% (≥2017) ( P < 0.001). In the 2017 and later cohort, logistic regression showed shorter disease duration (odds ratio [OR] 0.991, 95% confidence interval [CI] 0.987–0.996; P < 0.001) and myositis (OR 9.9, 95% CI 1.94–51.76; P = 0.006) were associated with therapy initiation, whereas switching was higher in patients with a higher modified Rodnan skin score (OR 1.03, 95% CI 1.00–1.06; P = 0.035) and in patients with arthritis (OR 3.03, 95% CI 1.55–5.94; P = 0.001). Last, combination therapy was associated with younger age, higher dyspnea class, and arthritis.
Conclusion
Our findings reveal a significant evolution in clinical practice. However, continued disease progression emphasizes the need for more effective therapeutic approaches. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Inflammation, Fibrosis and Ageing Initiative, Scientific Institute for Research Hospitalization and Healthcare San Raffaele Hospital, Vita-Salute San Raffaele…
- Department of Rheumatology, University of Bordeaux, Bordeaux, France.
- Department of Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Rheumatology, University of Naples Federico II, Italy.
- V.A. Nasanova Institute of Rheumatology, Moscow, Russia.
- Department of Internal Medicine and Clinical Immunology, Referral Centre for Rare Systemic Autoimmune Diseases North of France, North-West, Mediterranean and Guadeloupe, Centre Hospitalier Universitaire de Lille, Univer…
ORCID-Profile: Corrado Campochiaro, Madelon Vonk, Giacomo De Luca, Daniel E Furst
Zitieren
APA
Campochiaro, C., Truchetet, M. E., Vonk, M., De Luca, G., Cuomo, G., Ananieva, L. P., Hachulla, E., Smith, V., Gheorghiu, A. M., Becvar, R., Carreira, P., Hunzelmann, N., Furst, D. E., Ortiz-Santamaria, V., Del Galdo, F., Matucci-Cerinic, M., Hoffmann-Vold, A. M., & EUSTAR collaborators (2026). Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database. Arthritis & Rheumatology. https://doi.org/10.1002/art.70043
Vancouver
Campochiaro C, Truchetet ME, Vonk M, De Luca G, Cuomo G, Ananieva LP, et al. Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database. Arthritis & Rheumatology. 2026. doi:10.1002/art.70043
BibTeX
@article{Campochiaro2026,
author = {Campochiaro, Corrado and Truchetet, Marie-Elise and Vonk, Madelon and De Luca, Giacomo and Cuomo, Giovanna and Ananieva, Lidia P and Hachulla, Eric and Smith, Vanessa and Gheorghiu, Ana Maria and Becvar, Radim and Carreira, Patricia and Hunzelmann, Nicolas and Furst, Daniel E and Ortiz-Santamaria, Vera and Del Galdo, Francesco and Matucci-Cerinic, Marco and Hoffmann-Vold, Anna-Maria and EUSTAR collaborators, EUSTAR collaborators},
title = {Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70043}
}
EUVIMED